for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Immunomedics reports promising early-stage data from cancer drug study

Sept 18 (Reuters) - Immunomedics, Inc said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.

On Sunday, Gilead Sciences inc said it would buy Immunomedics for $21 billion. (Reporting by Manas Mishra in Bengaluru)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up